PKC-epsilon inhibitors
AssigneeThe Regents of the University of California
InventorsRobert Owen Messing, Michael A. Pleiss
Life of this patent
Estimating the term…
Abstract
The present invention relates to new AGC kinase inhibitors, in particular to compounds of Formula I or II or a stereoisomer, tautomer, racemic, metabolite, pro- or pre-drug, salt, hydrate, or solvate thereof, wherein Ar, Cy, R1, R3, p and n have the meaning defined in the claims. In particular, the present invention relates to more specifically AGC kinases inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease.
Claims9
A compound of Formula I or a salt thereof;
- wherein
- Ar is pyridyl;
- Cy is selected from the group consisting of cyclohexyl, adamantyl, and piperidinyl;
- n is 0 or 1;
- R1 is selected from:
- and
- with the proviso that when n is 0, then R1 is
- A is oxygen or sulfur;
- R5, R6, and R7 are each independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, or heterocylyl, where the cycloalkyl or heterocyclyl group may be fused to one phenyl or pyridyl group, and where each of said alkyl, cycloalkyl, heterocyclyl, phenyl or pyridyl groups is optionally substituted by halo, cycloalkyl, phenyl, or pyridyl.
A compound is selected from Table 1:
- TABLE 1
- Compound
- or a salt thereof.
A compound selected from Table 2:
- TABLE 2
- Compound
- or a salt thereof.
A compound selected from Table 3:
- TABLE 3
- Compound
- or salt thereof.
Dependencies are inferred from the claim text.